Have an account? Log in.
I don't have an account.
BioHarvest Sciences (NASDAQ:BHST) sees FY2026 sales of $42.000 million-$48.000 million vs $48.432 million analyst estimate.
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 41.18 percent increase over losses of $(0.17) per share from the
With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a proprietary cell bank will be propagated in liquid medium to generate significant biomass. Once stage 2 commences, this